Lexicon Pharmaceuticals Secures $100M Non-Dilutive Loan Facility from Hercules Capital
LXRX has more than doubled off its 52-week low of $0.514.
Summary
Lexicon Pharmaceuticals announced a new loan facility with Hercules Capital (HTGC) providing up to $100 million in borrowing capacity. An initial $55 million tranche was funded at closing to repay an existing loan, with the remaining $45 million available in tranches upon achieving certain clinical, regulatory, and financial milestones. This non-dilutive financing significantly enhances Lexicon's financial flexibility, offering an extended interest-only period and a maturity date of May 2030. This is a material capital event for Lexicon, supporting its upcoming regulatory and commercial milestones for its late-stage cardiometabolic programs. Traders should monitor the company's progress on these milestones to assess the draw-down of the additional tranches and the strategic deployment of this capital.
At the time of this announcement, LXRX was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $677.9M. The 52-week trading range was $0.51 to $1.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.